Compare DexCom, Inc. (DXCM) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Global E Online Ltd — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Global E Online Ltd trades at $40.26 (market cap $6.75B). The key difference: DexCom, Inc. is far larger — about 4.7× Global E Online Ltd's market cap, and DexCom, Inc. is more actively traded (3,607,070 versus 1,468,708). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Global E Online Ltd for 21 Days on average.
| DXCM | GLBE | |
|---|---|---|
Market Cap | $31.86B | $6.75B |
Volume | 3,607,070 | 1,468,708 |
Sector | Health | Consumer Cyclical |
52-Week High | $92.34 | $42.36 |
52-Week Low | $54.84 | $27.54 |
Typical Hold Time | 62 Days | 21 Days |
Enterprise Value | $31.32B | $6.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
GLBE trades at $38.96, up 0.67% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates, and raised its full-year 2026 outlook. Revenue grew 39% year-over-year in Q2, with an adjusted EBITDA margin expansion to 20.9%. Analyst consensus is strongly bullish with a $48.86 price target, though recent insider selling and a high P/E ratio of 45.65 warrant attention.
The outlook for GLBE is positive based on robust revenue growth and raised guidance, but risks include high valuation multiples and insider selling activity. The stock presents a growth opportunity if execution continues, yet investors should weigh the premium valuation against future earnings potential amid competitive e-commerce markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
